Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-3614
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-3614 is a small molecule drug initially developed by Merck Sharp & Dohme Corp. It is being investigated primarily for cardiovascular diseases, specifically targeting hypertension. The drug's mechanism of action details are not explicitly provided in the available data, but it is designed to affect cardiovascular parameters such as the aortic augmentation index and heart rate. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in male participants with mild to moderate hypertension. The development status remains pending with phase 1 clinical trials completed[1][3][5].
Beyond the preview
Go deeper on MK-3614.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-3614.